Text
Translating Molecular Discoveriaes Into New Therapies for Pulmonary Arterial Hypertension
Many of the drugs currrently in use for pulmonary arteial hypertension (PAH) were based on the vasodilator hypothesis in PAH therapeutics, oral endothelin-receptor antagonists, and oral phosphothelin receptor antagonis, and oral phosphodiesterase type 5 inhibitors. Our understanding of the factors involved dramatically over the past decade and has led to the development of newer therapeutic stratedies that target these processes. This neview will address the cellular and molecular processes implicated in clinical genetic, and experimental studies as underiying pulmonary vascular abnomalities associated with PAH.
Tidak tersedia versi lain